Elevance Health Inc. (NYSE:ELV) Q2 2025 Earnings Preview

• Earnings Expectation: Analysts predict an EPS of $9.20 and revenues of $48.26 billion.
• Historical Performance: ELV has a history of positive one-day returns in 55% of cases following earnings announcements over the past five years.
• Financial Health Indicators: Key financial metrics include a P/E ratio of approximately 12.86 and a debt-to-equity ratio of about 0.71.

Elevance Health Inc. (NYSE:ELV) is a prominent player in the health insurance industry, preparing to release its second-quarter 2025 earnings on July 17. Analysts expect the company to report earnings per share (EPS) of $9.20, with projected revenues of approximately $48.26 billion. This release is significant as it could influence the health insurance sector, especially with recent developments involving competitors like UnitedHealth Group and Centene Corp.

Historically, ELV has shown positive one-day returns in 55% of cases following earnings announcements over the past five years. The median positive return on these days was 2.7%, with the highest reaching 7.7%. Traders often employ strategies such as pre-earnings positioning, based on historical probabilities, and post-earnings positioning, which involves waiting for the announcement to assess returns before making trading decisions.

Despite the anticipated revenue growth of 11.4% compared to the previous year, driven by product and premium revenues and the expansion of CarelonRx, ELV's earnings may face pressure. Rising costs and a decrease in Medicaid memberships are contributing factors. Higher benefit and interest expenses, which have increased by nearly 11% year-over-year, are likely to impact profit margins.

The earnings estimate for the quarter has decreased by 1.8% over the past 60 days, indicating a 9.1% decline in earnings compared to the same period last year. This decline reflects the challenges ELV faces in maintaining profitability amidst rising expenses. The company's financial metrics, such as a price-to-earnings (P/E) ratio of approximately 12.86 and a price-to-sales ratio of about 0.41, provide insight into its market valuation.

ELV's enterprise value to sales ratio is around 0.54, reflecting its total valuation compared to revenue. The enterprise value to operating cash flow ratio is approximately 20.31, indicating how the company's valuation compares to its cash flow from operations. With an earnings yield of about 7.77% and a debt-to-equity ratio of approximately 0.71, ELV's financial health and leverage level are crucial factors for investors to consider. The current ratio of around 1.43 suggests the company's ability to cover short-term liabilities with short-term assets.